Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside

Journal of Nuclear Medicine

Volumn 46, Issue 1, 2005, Pages 106-113

  Piert, Morand ^a,e   Machulla, Hans Jürgen ^b   Picchio, Maria ^c   Reischl, Gerald ^b   Ziegler, Sybille ^a   Kumar, Piyush ^d   Wester, Hans Jürgen ^a   Beck, Roswitha ^a   McEwan, Alexander J B ^d   Wiebe, Leonard I ^d   Schwaiger, Markus ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d UNIVERSITY OF ALBERTA   (Canada)

^e UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

18F fluoroazomycin arabinoside; Mouse tumor model; PET tracers; Tumor hypoxia

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; ARABINOSIDE; CARBOGEN; FLUOROAZOMYCIN ARABINOSIDE F 18; OXYGEN; UNCLASSIFIED DRUG; 1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FLUOROAZOMYCIN ARABINOSIDE; MISONIDAZOLE; NITROIMIDAZOLE DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

AMBIENT AIR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTORADIOGRAPHY; CHEMICAL STRUCTURE; CONTROLLED STUDY; ELECTRODE; FEMALE; HYPOXEMIA; HYPOXIA; MOUSE; NONHUMAN; OXYGEN SENSING; OXYGENATION; POSITRON EMISSION TOMOGRAPHY; PRESSURE; PRIORITY JOURNAL; TISSUE OXYGENATION; TUMOR; ANIMAL; ANTIBODY SPECIFICITY; BAGG ALBINO MOUSE; CELL HYPOXIA; COMPARATIVE STUDY; DISEASE MODEL; EVALUATION; METABOLIC CLEARANCE RATE; METABOLISM; NEOPLASM; NUDE MOUSE; OXIDATION REDUCTION REACTION; SCINTISCANNING; TISSUE DISTRIBUTION; VALIDATION STUDY;

ANIMALS; CELL HYPOXIA; DISEASE MODELS, ANIMAL; FEMALE; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED BALB C; MICE, NUDE; MISONIDAZOLE; NEOPLASMS; NITROIMIDAZOLES; ORGAN SPECIFICITY; OXIDATION-REDUCTION; OXYGEN; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION;

EID: 15044349250     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Fyles AW, Milosevic M, Wong R, et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol. 1998;48:149-156.
2. Nordsmark M, Hoyer M, Keller J, Nielsen OS, Jensen OM. Overgaard J. The relationship between tumor oxygenation and cell proliferation in human soft tissue sarcomas. Int J Radiat Oncol Biol Phys. 1996;35:701-708.
3. Stadler P, Becker A, Feldmann H, et al. Influence of the hypoxic subvolume on the survival of patients with head and neck cancer. Int J Radiat Oncol Biol Phys. 1999;44:749-754.
4. Molls M, Stadler P, Becker A, Feldmann HJ, Dunst J. Relevance of oxygen in radiation oncology: mechanisms of action, correlation to low hemoglobin levels. Strahlenther Onkol. 1998;174(suppl 4):13-16.
5. Brizel DM, Dodge RK, Clough RW, Dewhirst MW. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol. 1999;53:113-117.
6. Harrison LB, Chadha M, Hill RJ, Hu K, Shasha D. Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist. 2002;7:492-508.
7. Stadler P, Feldmann HJ, Creighton C, et al. Clinical evidence for correlation of insufficient tissue oxygen supply (hypoxia) and tumor-associated proteolysis in squamous cell carcinoma of the head and neck. Int J Biol Markers. 2000;15: 235-236.
8. Teicher BA. Angiogenesis and cancer metastases: therapeutic approaches. Crit Rev Oncol Hematol. 1995;20:9-39.
9. 60Cu-ATSM. Eur J Nucl Med. 2003;30:844-850.
10. Raleigh JA, Dewhirst MW, Thrall DE. Measuring tumor hypoxia. Semin Radiat Oncol. 1996;6:37-45.
11. Chapman JD. Hypoxic sensitizers: implications for radiation therapy. N Engl J Med. 1979;301:1429-1432.
12. 123I-IAZA. Braz Arch Biol Technol. 2002; 45:S89-S102.
13. Wiebe L. PET radiopharmaceuticals for metabolic imaging in oncology. In: Tamaki Y, Kuge Y, eds. PET and Molecular Imaging: State of the Art and Future Perspectives. International Congress Series 1264C. Amsterdam, The Netherlands: Elsevier; 2003:53-76.
14. Nunn A, Linder K, Strauss HW. Nitroimidazoles and imaging hypoxia. Eur J Nucl Med. 1995;22:265-280.
15. Machulla H-J. Imaging of Hypoxia. Dordrecht, The Netherlands: Kluwer Academic Publishers; 1999.
16. 18F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression. Eur J Nucl Med. 2003;30:695-704.
17. 18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys. 1996;24:417-428.
18. Koh W, Rasey J, Evans M, et al. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys. 1992;22:199-212.
19. Koh W, Bergman K, Rasey J, et al. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys. 1995;22:391-398.
20. Piert M, Machulla H, Becker G, et al. Introducing fluorine-18 fluoromisonidazole positron emission tomography for the localisation and quantification of pig liver hypoxia. Eur J Nucl Med. 1999;26:95-109.
21. 18F]fluoromisonidazole uptake on oxygen delivery and tissue oxygenation in the porcine liver. Nucl Med Biol 2000;27:693-700.
22. 18F]fluoroerythronitroimidazole PET. J Nucl Med. 2001;42:1643-1652.
23. Zanzonico P, O'Donoghue J, Chapman JD, et al. Iodine-124-labeled iodoazomycin-galactoside imaging of tumor hypoxia in mice with serial microPET scanning. Eur J Nucl Med Mol Imaging. 2004;31:117-128.
24. 18F]fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia. J Nucl Med. 1999;40:1072-1079.
25. Parliament MB, Wiebe LI, Franko AJ. Nitroimidazole adducts as markers for tissue hypoxia: mechanistic studies in aerobic normal tissues and tumour cells. Br J Cancer. 1992;66:1103-1108.
26. Mannan RH, Somayaji VV, Lee J, Mercer JR, Chapman JD, Wiebe LI. Radioiodinated 1-(5-iodo-5-deoxy-beta-D-arabinofuranosyl)-2-nitroimidazole (iodoazomycin arabinoside: IAZA): a novel marker of tissue hypoxia. J Nucl Med. 1991;32: 1764-1770.
27. 18F] fluoromisonidazole by nucleophilic substitution on THP-protected precursor: yield dependence on reaction parameters. J Radioanal Nucl Chem. 1999;240:925-927.
28. 18F-FAZA, a new tracer for hypoxia [abstract]. J Nucl Med. 2002;43(suppl): 364P.
29. Papadopoulou MV, Ji M, Bloomer WD. Schedule-dependent potentiation of chemotherapeutic drugs by the bioreductive compounds NLCQ-1 and tirapazamine against EMT6 tumors in mice. Cancer Chemother Pharmacol. 2001; 48:160-168.
30. Wester HJ, Schottelius M, Scheidhauer K, Reubi JC, Wolf I, Schwaiger M. Comparison of radioiodinated TOC, TOCA and Mtr-TOCA: the effect of carbohydration on the pharmacokinetics. Eur J Nucl Med Mol Imaging. 2002;29:28-38.
31. Rafecas M, Boning G, Pichler BJ, Lorenz E, Schwaiger M, Ziegler SI. Inter-crystal scatter in a dual layer, high resolution LSO-APD positron emission tomograph. Phys Med Biol. 2003;48:821-848.
32. Ziegler SI, Pichler BJ, Boening G, et al. A prototype high-resolution animal positron tomograph with avalanche photodiode arrays and LSO crystals. Eur J Nucl Med. 2001;28:136-143.
33. Böning G, Pichler BJ, Rafecas M, Lorenz E, Schwaiger M, Ziegler SI. Implementation of Monte Carlo coincident aperture functions in image generation of a high resolution animal positron tomograph. IEEE Trans Nucl Sci. 2001;48:805-810.
34. Kumar P, Wiebe LI, Asikoglu M, Tandon M, McEwan AJ. Microwave-assisted (radio)halogenation of nitroimidazole-based hypoxia markers. Appl Radiat Isot. 2002;57:697-703.
35. 3H-labelling and preliminary biological evaluation of a novel 2-nitroimidazole marker of tissue hypoxia. J Labelled Compds Radiopham. 1999;42:3-16.
36. 18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. Nucl Med Biol. 2003;30:317-326.
37. 99mTc]HL-91: correlation with microelectrode measurements. J Nucl Med. 2001; 42:337-344.
38. Chapman JD, Zanzonico P, Ling CC. On measuring hypoxia in individual tumors with radiolabeled agents. J Nucl Med. 2001;42:1653-1655.
39. Lythgoe MF, Williams SR, Busza AL, et al. The relationship between magnetic resonance diffusion imaging and autoradiographic markers of cerebral blood flow and hypoxia in an animal stroke model. Magn Reson Med. 1999;41:706-714.